Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 3.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 218,544 shares of the company's stock after selling 6,829 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.36% of Rhythm Pharmaceuticals worth $12,234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Voloridge Investment Management LLC boosted its stake in shares of Rhythm Pharmaceuticals by 7.7% during the fourth quarter. Voloridge Investment Management LLC now owns 380,537 shares of the company's stock valued at $21,302,000 after purchasing an additional 27,214 shares in the last quarter. Two Sigma Advisers LP increased its holdings in shares of Rhythm Pharmaceuticals by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 13,100 shares of the company's stock valued at $733,000 after acquiring an additional 300 shares during the period. State of Wyoming bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth $61,000. Stempoint Capital LP raised its position in shares of Rhythm Pharmaceuticals by 404.1% in the 4th quarter. Stempoint Capital LP now owns 208,016 shares of the company's stock worth $11,645,000 after acquiring an additional 166,748 shares in the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of Rhythm Pharmaceuticals by 31.3% during the 4th quarter. ProShare Advisors LLC now owns 18,328 shares of the company's stock worth $1,026,000 after purchasing an additional 4,370 shares during the last quarter.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, EVP Yann Mazabraud sold 75,000 shares of the firm's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the sale, the executive vice president now owns 40,370 shares in the company, valued at approximately $2,078,247.60. This trade represents a 65.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Pamela J. Cramer sold 20,760 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, April 8th. The shares were sold at an average price of $60.14, for a total transaction of $1,248,506.40. Following the completion of the transaction, the insider now directly owns 19,209 shares of the company's stock, valued at $1,155,229.26. The trade was a 51.94% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 127,630 shares of company stock worth $7,107,346. Insiders own 6.10% of the company's stock.

Rhythm Pharmaceuticals Price Performance

Rhythm Pharmaceuticals stock traded up $2.01 during trading hours on Tuesday, hitting $65.67. 757,157 shares of the stock traded hands, compared to its average volume of 555,653. The firm's 50 day moving average price is $59.98 and its 200-day moving average price is $57.65. The stock has a market capitalization of $4.18 billion, a price-to-earnings ratio of -15.17 and a beta of 2.36. Rhythm Pharmaceuticals, Inc. has a 1 year low of $37.46 and a 1 year high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.12). The firm had revenue of $37.72 million during the quarter, compared to analysts' expectations of $40.43 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. Rhythm Pharmaceuticals's quarterly revenue was up 25.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.35) EPS. Research analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RYTM has been the topic of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a research note on Tuesday, April 8th. Needham & Company LLC raised their price target on shares of Rhythm Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, May 7th. Bank of America upgraded shares of Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective for the company in a research note on Monday, April 7th. Morgan Stanley restated an "overweight" rating and issued a $72.00 target price on shares of Rhythm Pharmaceuticals in a research note on Friday, March 7th. Finally, Stifel Nicolaus upped their price target on Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Thirteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Rhythm Pharmaceuticals has an average rating of "Buy" and a consensus target price of $76.62.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.